View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
September 27, 2016

EMA and FDA establish new cluster to support medicine development for rare diseases

The European Medicines Agency (EMA) and the United States Food and Drug Administration (FDA) have established a new cluster to boost the development of medicines for rare diseases.

By Srijanee Chakraborthy

The European Medicines Agency (EMA) and the United States Food and Drug Administration (FDA) have established a new cluster to boost the development of medicines for rare diseases.

The new cluster will share information and best practices on each other’s regulatory approach to support medicine development for these diseases.

It will provide a forum for confidential exchange of authorities draft documents, policies under development, and furnish detailed information to support the scientific basis for decision making for the medicine development.

The recent activity is a part of the regulatory authority’s objective to expand international collaboration.

"The new cluster will share information and best practices on each other’s regulatory approach to support medicine development for these diseases."

A global collaboration on this area has been deemed important to ensure the number of studies conducted benefit patients regardless of their location.

The information being exchanged in the cluster will range from design of clinical trials in small populations, use of statistical analysis methods to selection of trial endpoints and pre-clinical evidence to support development programmes.

The authorities will also discuss design of post-marketing studies such as EMA’s conditional marketing authorisation and FDA’s accelerated approval, as well as risk management strategies addressing long-term safety issues with medicines for rare diseases.

The cluster will be jointly chaired by EMA and FDA and initially meet each month through a teleconference.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology